Contrarily, Candelaria et al. reported a significant reversal of gemcitabine resistance by hydralazine in cervical cancer cells via upregulation of the drug transporter SLC29A1 and the rate-limiting activating gene dCK [46]. Here, SLC29A1 is linked to cervical carcinoma.